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Abstract
Current Centers for Disease Control and Prevention (CDC) guidelines for prescribing pre-exposure prophylaxis
(PrEP) to prevent HIV transmission are broad. In order to better characterize groups who may benefit most from
PrEP, we reviewed demographics, behaviors, and clinical outcomes for individuals presenting to a publicly-
funded sexually transmitted diseases (STD) clinic in Providence, Rhode Island, from 2012 to 2014. Latent class
analysis (LCA) was used to identify subgroups of men who have sex with men (MSM) at highest risk for
contracting HIV. A total of 1723 individuals presented for testing (75%male; 31%MSM).MSMweremore likely
to test HIV positive than heterosexual men or women. Among 538MSM, we identified four latent classes. Class 1
had the highest rates of incarceration (33%), forced sex (24%), but had no HIV infections. Class 2 had <5 anal sex
partners in the previous 12 months, the lowest rates of drug/alcohol use during sex and lower HIV prevalence
(3%). Class 3 had the highest prevalence of HIV (7%) and other STDs (16%), > 10 anal sex partners in the previous
12months (69%), anonymous partners (100%), drug/alcohol use during sex (76%), and prior STDs (40%). Class 4
had similar characteristics and HIV prevalence as Class 2. In this population, MSM who may benefit most from
PrEP include those who have >10 sexual partners per year, anonymous partners, drug/alcohol use during sex and
prior STDs. LCA is a useful tool for identifying clusters of characteristics that may place individuals at higher risk
for HIV infection and who may benefit most from PrEP in clinical practice.
Introduction
Approximately 50,000 individuals are newly infectedwith HIV each year in the United States (US).1 HIV
continues to impact gay, bisexual, and other men who have
sex with men (MSM) disproportionately. In 2011, more than
78% of all new HIV diagnoses in the US were among MSM,
with a disproportionate number of infections among males
age 13–24 years old.1 MSM of color are also disproportion-
ately impacted by HIV. Of all MSM diagnosed with HIV in
2011, 38% were African American and 24% were Hispanic.
Other populations at high risk for acquiring HIV include men
and women in serodiscordant partnerships, commercial sex
workers, individuals with multiple sexual partners, and in-
dividuals diagnosed with other sexually transmitted diseases
(STDs).2–5
Pre-exposure prophylaxis (PrEP) is a once-daily anti-
retroviral medication (emtricitabine/tenofovir) that is used to
prevent HIV infection. Approved by the US Food and Drug
Administration in July 2012, PrEP has been demonstrated to be
safe and effective in multiple at-risk populations.6 Among
MSM, PrEP was associated with a greater than 90% efficacy
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in those with detectable levels of medication in their blood.7
PrEP is also efficacious in other populations, including high-
risk heterosexuals and people who inject drugs (PWID).7–10
The success of PrEP in clinical trials now gives way to ques-
tions regarding how implementation and dissemination of PrEP
will be executed in real-world settings.11Given that STDclinics
routinely provide care to those at highest-risk forHIV infection,
they may be an ideal place to implement PrEP programs.12
Commonly cited concerns about PrEP implementation in-
clude side-effects, cost of medications, increased risk behav-
iors while taking PrEP, and the potential for drug resistance
during seroconversion.11 Current Centers for Disease Control
and Prevention (CDC) guidelines recommend reserving PrEP
for individuals at highest risk for acquiring HIV.13 The
guidelines suggest that populations who may benefit most
from PrEP include: MSM who have had at least one act of
condomless anal sex in the last year; MSM who have been
recently diagnosed with an STD; andMSM in a serodiscordant
relationship with an HIV-positive partner. These broad criteria
may be less than optimal for identifying men who are at
highest risk for acquiring HIV. Factors including medication
cost, available clinical resources, and potential for long-term
side-effects may limit broad PrEP implementation to the
general population of MSM. Effective use of resources re-
quires identification of the highest-risk subgroups of MSM to
help inform PrEP implementation programs.
In this study, we use latent class analysis (LCA) to char-
acterize risk factors for HIV infection among individuals
presenting to an urban STD clinic. We build upon previous
studies on individual risk behaviors14–17 to identify groups of
individuals who are at highest risk for HIV infection and
candidates for PrEP. The results of this study will help guide
individual clinicians on PrEP use and, importantly, policy-
level PrEP planning as programs are implemented in the US.
LCA is a statistical analysis that uncovers subgroups, or
‘‘classes’’ defined by distinct response patterns on multiple
HIV risk factors. LCA has been used to evaluate substance
use,18–23 HIV risk factors,24–26 medication adherence,27 and
other HIV behaviors,28–30 but has not been widely used to
elucidate classes of MSM who may benefit most from PrEP.
Unlike traditional regression approaches that evaluate the
average effects of risk factors on HIV risk and can add only a
few interaction terms before becoming too difficult to inter-
pret, LCA assesses the differential effects of multiple risk
factors simultaneously. In essence, LCA evaluates the inter-
action and patterns of multiple risk factors to identify indi-
viduals at greatest risk for HIV.31 This methodology allows
for the identification of specific subgroups of MSM with
distinct patterns of high-risk behaviors, which can then inform
targeting of HIV preventions interventions such as PrEP.
The objective of this study was to evaluate the behavioral
risk profiles of individuals presenting to an urban STD clinic
in order to identify distinct subgroups of individuals at




The Miriam Hospital STD Clinic is the only publicly-
funded STD clinic in the state of Rhode Island. All individuals
presenting for HIV or STD testing complete a one-page intake
form, which includes demographics, behavioral risk factors,
and other conventional HIV surveillance information. We
collected de-identified patient data for all individuals pre-
senting for testing between January 2012 and May 2014. We
reviewed the following surveillance data: age, gender, race,
ethnicity, risk behaviors, state of residence, insurance status,
prior HIV and STD testing, injection drug use, and number of
sex partners in the last 12 months (oral, vaginal, and/or anal).
Other behavioral data included sexwith anonymous partner(s),
alcohol or drug use during sex, sex with someone of unknown
HIV status, sex with someone who exchanges sex for drugs or
money, history of exchanging drugs or money for sex, having
ever been forced to have sex, and prior history of incarceration.
Sexual behavior categories included: MSM (exclusively),
men who have sex exclusively with women (MSW), men
who have sex with men and women (MSMW), women who
have sex exclusively with men (WSM), women who have sex
exclusively with women (WSW), and women who have sex
with men and women (WSWM). HIV (antibody testing),
syphilis (treponemal and non-treponemal), gonorrhea (urine
nucleic acid amplification testing, NAAT), and chlamydia
(urine NAAT) results were reviewed for all individuals.
Rectal and pharyngeal NAAT testing for gonorrhea and
chlamydia was performed in a small subset of MSM with
symptoms, but otherwise not routinely performed.
Bivariate analyses including the chi-square test were used
to compare demographics and behaviors between groups.
Significance was defined as alpha less than 0.05 and all re-
ported p-values were two-sided. This study was approved by
The Miriam Hospital’s Institutional Review Board.
Latent class analysis
LCA was used to identify groups of individuals at highest
risk for HIV based on specific variables. The purpose of this
analysis was to identify groups of individuals who had a
higher prevalence of HIV in order to better understand how to
implement PrEP. LCA32,33 is a statistical approach that
generates latent classes based on patterns of data, with the
goal of grouping similar individuals. A series of LCAmodels
with between one and five classes was tested using the Mplus
software package Version 7.1 (Muthe´n and Muthe´n, 1998–
2013). To avoid the likelihood of converging on a local
maximum, 500 start values were generated for each model.
Indices used to determine the best model fit and thus the
optimal LCA solution included the Akaike Information Cri-
terion (AIC), sample size adjusted Bayesian Information
Criterion (BIC), which are measures of the relative fit of a
statistical model to a set of data compared to other models
and used for model selection (lower AIC and BIC values
indicate better model fit), and the bootstrapped likelihood
ratio test (BLRT) for model fit,34 which tests the null hy-
pothesis of no improvement in fit for the model under con-
sideration compared to a model with one less class.
Entropy, which measures the extent to which classes are
distinct from each other, the average posterior probability of
class membership, and interpretability of the classes were
also considered. Entropy values above 0.8 indicate better
distinction of classes.35
Variables used in the LCA included: date of last HIV test,
number of oral sex partners in the last 12 months, number of
anal sex partners in the last 12 months, any anonymous
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partner(s) in the last 12 months, alcohol or drug use during sex
in the last 12months, sexwith a partner of unknownHIV status
in the last 12months, prior STDdiagnosis in the last 12months,
exchanging sex for money/drugs or sex with someone who
exchanges sex for money/drugs, prior injection drug use,
having been ever forced to have sex, and prior history of in-
carceration.
Demographic covariates included age, race, and ethnicity.
Outcomes of primary interest included testing positive for
HIV or other STDs (i.e., syphilis, gonorrhea, and/or chla-
mydia) at the clinic visit. After identifying the LCA model
with the optimal number of classes based on these criteria,
multinomial logistic regression was used to compare classes
on demographic covariates, including age, race, and ethnic-
ity, and on outcomes including testing positive for HIV or
another STD.
Results
A total of 1723 individuals presented for HIV and/or STD
testing during the study period (Table 1). Among these, 75%
were male, 52% were less than 30 years old, 70% were
Caucasian/white, 18% African American/black, and 23%
Hispanic. Sexual preference included MSM (26%), MSMW
(5%), MSW (43%), WSM (22%), WSWM (2%), and WSW
(1%). Of the whole cohort, 29% reported a prior STD diag-
nosis in their lifetime. Seventy-six percent of individuals had
been previously tested for HIV. Among those tested, 1.5%
were found to be positive for HIV, 4.4% for syphilis, 2.6% for
gonorrhea and 8.9% for chlamydia. In total, 11.7% of indi-
viduals tested positive for at least one STD.
Compared to non-MSM, MSM were more likely to test
positive for HIV (96%, 22/23 of cases in MSM vs. 4%, 1/23
cases in non-MSM, p < 0.01); syphilis (86%, 59/69 vs. 14%,
10/69, p < 0.01); and gonorrhea (59%, 24/41 vs. 41%, 17/41,
p < 0.01, Table 1). Non-MSM were more likely to test posi-
tive for chlamydia than MSM (81%, 113/139 of cases in non-
MSM vs. 19%, 26/139 cases in MSM, p< 0.01).
Of the 538MSM presenting for testing, 4.1%were positive
for HIV. In the bivariate analyses, MSM who tested positive
for HIV were much more likely to have a history of prior IDU
(14% vs. 3%, p < 0.01) and of being forced to have sex (27%
vs. 5%, p < 0.01, Table 2). There was no difference between
MSM who tested positive for HIV compared to those who
were HIV negative and age group, race, ethnicity, prior HIV
testing, number of sex partners in the preceding 12 months
(anal or oral or both), anonymous partners, prior STD diag-
nosis ever or in the preceding 12 months, exchanging sex for
money/drugs, sex with someone who exchanges sex for
money/drugs, or history of incarceration. There was no dif-
ference between MSM who did and did not test positive for
any STD and any of the variables tested.
In the LCA, a total of 449 MSM were included who had
complete demographic, behavioral, and clinical data avail-
able. A comparison of model fit indices demonstrated that a
four-class solution was preferable (Table 3). Compared to
models that contained one to three classes, the four-class
solution provided the lowest BIC and AIC values, indicating
the best model fit, and good entropy (0.81), suggesting ad-
equate distinction of classes, with a significant improve-
ment in model fit over other models by the BLRT. Although
entropy was higher for the five-class model (0.84), the
decrease in the AIC and BIC between the four- and five-
class model was minimal, and the BLRT suggested no im-
provement in fit for the five-class model over the four-class
model ( p = 0.20). The average probability of latent class
membership was 0.87 for Class 1, 0.89 for Class 2, 0.90 for
Class 3, and 0.92 for class 4 (Table 3).
As shown in Table 4, Class 1 (N = 33) was evenly dis-
tributed across age and over one-fifth were Hispanic (21%).
This class had the lowest percent of individuals who had
never had an HIV test (28%), as well as lowest number of
reported oral and anal sex partners (82% and 85%with <1 oral
and anal sex partners in the past 12months, respectively). This
class also had the highest proportion of past incarceration
(33%), history of having been forced to have sex (24%), and
sex with a partner of unknown status (67%). A prior STD
in the last 12 months was lowest in this group. Class 1 did
not contain any HIV positive individuals and had a low
proportion (6%) of members testing positive for any STD
(Tables 4 and 5).
Class 2 (N = 142) had a similar distribution of age and
race/ethnicity as Class 1. Approximately half (56%) re-
ported never HIV testing. Class 2 had the highest proportion
reporting one or two oral and anal sex partners, and no
members reporting five or more sexual partners in the past
year. Class 2 had the lowest proportion reporting anony-
mous partners, alcohol and/or drug use during sex, sex with
partners of unknown HIV serostatus, or exchanging sex.
This class had the second-lowest HIV prevalence at 3%, and
13% of members of this class were positive for at least one
STD (Tables 4 and 5).
Class 3 (N = 55) was evenly distributed across age groups,
but had the largest number of Caucasian members (85%).
Sixty-eight percent had never had an HIV test and no one in
the class had been tested for HIV in the preceding year. In-
dividuals in Class 3 also had the largest number of oral sex
partners in the past 12 months; 100% reported >3 partners
and 69% >10 partners. These individuals also reported the
largest number of anal sex partners in the past 12 months; all
had had anal sex and 60% had >10 partners. One-hundred
percent of individuals in this class reported having had
anonymous sex partners.
This class also had the largest number of individuals who
had used alcohol or other drugs during sex (76%), exchanged
sex for drugs/money or had sex with someone who exchanges
sex for drugs/money (38%), had a STD in the preceding 12
months (40%), or had previously injected drugs (22%). Class
3 had the highest prevalence of HIV (7%) and the highest
prevalence of any STD (16%).
Class 4 (N = 219) was evenly distributed across age
groups, and had the lowest percent of Hispanic individuals
(14%). Similar to Class 2, slightly more than half reported
that they had never had an HIV test. Individuals in Class 4
more frequently reported having 5–10 oral and anal sex
partners than any other category, the second highest number
of partners second to Class 3. A larger percent of Class 4
reported sex with an anonymous partner (74%) and a history
of an STD in the last 12 months (19%) than any class except
Class 4. No members of Class 4 reported a history of in-
jection drug use or incarceration. Class 4 has the second-
highest HIV prevalence at 4% and second-highest STD
prevalence at 15% testing positive for any STD (Tables 4
and 5).
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Discussion
This LCA of MSM presenting for testing at the only
publicly-funded STD clinic in Rhode Island helped identify
patients who may benefit most from PrEP by identifying
groups of patients with differential HIV prevalence. Overall,
4.1% ofMSM presenting to the publicly funded STD clinic in
Rhode Island tested positive for HIV. MSM were also more
likely to test positive for syphilis and gonorrhea compared to
non-MSM.
Table 1. Demographic and Behavioral Characteristics of Patients Presenting for Care
at an Urban Sexually Transmitted Diseases (STD) Clinic in Providence, Rhode Island (2012–2014)
Total (N = 1,723) MSM (N = 538) Other (N = 1185)
% N % N % N p Value
Gender
Male 75% (1291/1723) 99% (534/538) 64% (757/1185) <0.01
Female 25% (428/1723) - 36% (428/1185)
Transgender 0.2% (4/1723) 1% (4/538) 0% (0/1185)
Age
15–19 4% (68/1723) 1% (8/538) 5% (60/1185) <0.01
20–24 25% (432/1723) 20% (107/538) 27% (325/1185)
25–29 23% (393/1723) 21% (113/538) 24% (280/1185)
30–34 15% (251/1723) 15% (80/538) 14% (171/1185)
35–39 9% (154/1723) 8% (42/538) 9% (112/1185)
40+ 25% (423/1723) 35% (187/538) 20% (236/1185)
Unknown 0% (2/1723) 0% (1/538) 0% (1/1185)
Race
Caucasian/white 70% (1206/1723) 78% (418/538) 66% (788/1185) <0.01
African American/black 18% (316/1723) 11% (60/538) 22% (256/1185)
Asian 3% (57/1723) 4% (24/538) 3% (33/1185)
Cape Verdean 1% (22/1723) 1% (7/538) 1% (15/1185)
Other/mixed 7% (122/1723) 5% (29/538) 8% (93/1185)
Ethnicity
Hispanic/Latino 23% (396/1723) 16% (86/538) 26% (310/1185) <0.01
Risk
MSM 26% (449/1723) 83% (449/538) -
MSMW 5% (89/1723) 17% (89/538) -
MSW 43% (744/1723) - 63% (744/1185)
WSM 22% (372/1723) - 31% (372/1185)
WSMW 2% (35/1723) - 3% (35/1185)
WSW 1% (13/1723) - 1% (13/1185)
N/A 1% (21/1723) - 2% (21/1185)
Prior HIV test 76% (1305/1723) 89% (477/538) 70% (828/1185) <0.01
Last HIV test
<1 year 50% (592/1179) 62% (267/428) 43% (325/751) <0.01
1–2 years 30% (358/1179) 26% (110/428) 33% (248/751)
2–5 years 12% (139/1179) 5% (22/428) 16% (117/751)
>5 years 8% (90/1179) 7% (29/428) 8% (61/751)
Sex with anonymous partner 35% (551/1560) 55% (251/457) 27% (300/1103) <0.01
Alcohol/drugs and sex 34% (523/1560) 34% (154/457) 33% (369/1103) 0.93
Partner with unknown HIV status 37% (582/1559) 45% (205/457) 34% (377/1102) <0.01
Exchanged sex for money/drugs 2% (34/1561) 4% (20/457) 1% (14/1104) <0.01
Sex with exchanger 7% (103/1561) 7% (33/457) 6% (70/1104) 0.52
Forced sex 5% (81/1561) 7% (32/457) 4% (49/1104) 0.04
Prior STD ever 29% (506/1720) 37% (200/538) 26% (306/1182) <0.01
STD last 12 months 13% (208/1561) 18% (82/457) 11% (126/1104) <0.01
Prior IDU 3% (57/1718) 4% (21/536) 3% (36/1182) 0.35
Incarcerated 10% (160/1561) 4% (19/457) 13% (141/1104) <0.01
HIV 2% (23/1519) 5% (22/451) 0% (1/1091) <0.01
Syphilis 4% (69/1582) 12% (59/498) 1% (10/1084) <0.01
Gonorrhea 3% (41/1567) 5% (24/463) 2% (17/1104) <0.01
Chlamydia 9% (139/1565) 6% (26/461) 10% (113/1104) <0.01
Any STD 12% (201/1723) 14% (78/538) 10% (123/1185) 0.01
IDU, injection drug use; MSM, men who have sex with men; MSW, men who have sex exclusively with women (MSW); MSMW, men
who have sex with men and women (MSMW); STD, sexually transmitted disease; WSM, women who have sex exclusively with men
(FSM); WSW, women who have sex exclusively with women (WSW); WSWM, women who have sex with men and women (WSWM).
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Table 2. Demographics and Behaviors of Men Who Have Sex with Men (MSM) Presenting for Care












% N % N % N p % N % N p
Age
15–19 1% (8/537) 0% (0/22) 2% (7/428) 0.55 0% (0/78) 2% (8/459) 0.28
20–24 20% (107/537) 23% (5/22) 20% (87/428) 22% (17/78) 20% (90/459)
25–29 21% (113/537) 27% (6/22) 21% (88/428) 26% (20/78) 20% (93/459)
30–34 15% (80/537) 5% (1/22) 16% (70/428) 15% (12/78) 15% (68/459)
35–39 8% (42/537) 14% (3/22) 7% (30/428) 12% (9/78) 7% (33/459)
40+ 35% (187/537) 32% (7/22) 34% (146/428) 26% (20/78) 36% (167/459)
Race
Caucasian/white 79% (418/530) 77% (17/22) 80% (336/422) 0.10 74% (56/76) 80% (362/454) 0.13
African American 11% (60/530) 14% (3/22) 10% (44/422) 17% (13/76) 10% (47/454)
Asian 5% (24/530) 0% (0/22) 5% (21/422) 3% (2/76) 5% (22/454)
Cape Verdean 1% (7/530) 0% (0/22) 2% (7/422) 3% (2/76) 1% (5/454)
Pacific Islander 0% (2/530) 0% (0/22) 0% (1/422) 1% (1/76) 0% (1/454)
Mixed 0% (2/530) 5% (1/22) 0% (1/422) 1% (1/76) 0% (1/454)
Other 3% (17/530) 5% (1/22) 3% (12/422) 1% (1/76) 4% (16/454)
Ethnicity
Hispanic/Latino 16% (86/531) 18% (4/22) 17% (70/422) 0.85 18% (14/76) 16% (72/455) 0.57
Prior HIV test (yes/no) 89% (477/537) 95% (21/22) 87% (371/428) 0.23 92% (72/78) 88% (405/459) 0.29
Last HIV test
<1 year 62% (267/428) 48% (10/21) 65% (227/351) 0.02 64% (45/70) 62% (222/358) 0.68
1–2 years 26% (110/428) 24% (5/21) 26% (93/351) 24% (17/70) 26% (93/358)
2–5 years 5% (22/428) 19% (4/21) 5% (16/351) 7% (5/70) 5% (17/358)
>5 years 7% (29/428) 10% (2/21) 4% (15/351) 4% (3/70) 7% (26/358)
Sex partners last 12 months (anal or oral)
0 1% (4/524) 0% (0/20) 0% (2/421) 0.37 1% (1/73) 1% (3/451) 0.17
1 14% (75/524) 15% (3/20) 13% (55/421) 11% (8/73) 15% (67/451)
2 16% (84/524) 10% (2/20) 18% (74/421) 15% (11/73) 16% (73/451)
3–4 19% (97/524) 10% (2/20) 18% (75/421) 10% (7/73) 20% (90/451)
5–10 34% (176/524) 30% (6/20) 35% (146/421) 40% (29/73) 33% (147/451)
10+ 17% (88/524) 35% (7/20) 16% (69/421) 23% (17/73) 16% (71/451)
Sex partners last 12 months (oral only)
0 5% (21/454) 13% (2/15) 4% (15/368) 0.33 6% (4/64) 4% (17/390) 0.17
1 16% (73/454) 20% (3/15) 15% (57/368) 13% (8/64) 17% (65/390)
2 17% (79/454) 0% (0/15) 18% (68/368) 11% (7/64) 18% (72/390)
3–4 20% (90/454) 20% (3/15) 20% (72/368) 14% (9/64) 21% (81/390)
5–10 31% (139/454) 33% (5/15) 30% (112/368) 42% (27/64) 29% (112/390)
10+ 11% (52/454) 13% (2/15) 12% (44/368) 14% (9/64) 11% (43/390)
Sex partners last 12 months (anal only)
0 8% (38/454) 7% (1/15) 8% (28/369) 0.34 6% (4/64) 9% (34/390) 0.12
1 24% (111/454) 27% (4/15) 25% (92/369) 19% (12/64) 25% (99/390)
2 16% (74/454) 13% (2/15) 18% (66/369) 17% (11/64) 16% (63/390)
3–4 18% (80/454) 0% (0/15) 17% (64/369) 11% (7/64) 19% (73/390)
5–10 25% (115/454) 47% (7/15) 24% (90/369) 39% (25/64) 23% (90/390)
10+ 8% (36/454) 7% (1/15) 8% (29/369) 8% (5/64) 8% (31/390)
Anonymous partner 55% (251/457) 60% (9/15) 55% (205/370) 0.73 61% (39/64) 54% (212/393) 0.30
Alcohol/drugs and sex 34% (154/457) 47% (7/15) 33% (122/370) 0.27 42% (27/64) 32% (127/393) 0.12
Partner with unknown
HIV status
45% (205/457) 67% (10/15) 45% (168/370) 0.11 48% (31/64) 44% (174/393) 0.54
Exchanged sex for
money/drugs
4% (20/457) 0% (0/15) 5% (17/370) 0.40 3% (2/64) 5% (18/393) 0.60
Sex with exchanger 7% (33/457) 7% (1/15) 7% (25/370) 0.99 6% (4/64) 7% (29/393) 0.75
Forced sex 7% (32/457) 27% (4/15) 5% (20/370) <0.01 9% (6/64) 7% (26/393) 0.42
Prior STD ever 37% (200/538) 41% (9/22) 31% (131/429) 0.31 44% (34/78) 36% (166/460) 0.21
STD last 12 months 18% (82/457) 13% (2/15) 15% (57/370) 0.83 20% (13/64) 18% (69/393) 0.59
Prior IDU 4% (21/536) 14% (3/22) 3% (13/428) <0.01 6% (5/78) 3% (16/458) 0.22
Incarcerated 4% (19/457) 7% (1/15) 4% (15/370) 0.62 3% (2/64) 4% (17/393) 0.66
PEP
Heard of 56% (302/538) 59% (13/22) 55% (234/429) 0.68 50% (39/78) 57% (263/459) 0.23
Taken 5% (29/538) 9% (2/13) 6% (24/234) 0.56 6% (5/39) 5% (24/263) 0.47
PrEP
Heard of 47% (254/538) 55% (12/22) 45% (194/429) 0.39 40% (31/78) 49% (223/459) 0.15
Taken 2% (10/538) 9% (2/12) 2% (8/194) 0.05 3% (2/31) 2% (8/223) 0.44
IDU, injection drug use; PEP, post-exposure prophylaxis; PrEP, pre-exposure prophylaxis; STD, sexually transmitted disease.
601
LCA revealed four distinct classes of MSM demonstrating
different characteristics and risk profiles. Among these, Class
1 had no HIV-positive individuals and the lowest rates of
STDs (6%). Individuals in Class 1 tended to have been pre-
viously tested for HIV and had fewer sex partners compared
to other classes. Class 1 also had the highest rate of incar-
ceration (33%) and of having been forced to have sex (24%).
Class 3 included MSMwith the highest rate of HIV (7%) and
other STDs (16%). A significant number (68%) of MSM in
Class 3 had never had an HIV test and over 60% had >10 anal
sex partners in the preceding year; 100% of this class reported
having had anonymous sex partners. Class 3 had the largest
number of MSM who were reported using alcohol or drugs
during sex (76%), exchanging sex for drugs/money or having
sex with someone who exchanges sex for drugs/money
(38%), having a prior STD in the preceding 12months (40%),
or using injection drugs (22%). Interestingly, 55% (12/22) of
newly diagnosedMSM had heard of PrEP, including 100% of
those in the highest-risk class who tested positive.
These analyses helped identify groups of MSM who are
at highest risk of HIV and may be ideal candidates for PrEP
in the setting of an urban STD clinic. Previous evidence has
demonstrated significant HIV risk behavior immediately
preceding a new HIV diagnosis.36 In our STD clinic, when
individuals are identified as having behaviors associated with
the highest risk class (i.e., a large number of partners, anon-
ymous partners, alcohol and/or drug use during sex, etc.), they
receive more intensive counseling and education related to
PrEP. In addition, identification of these classes has guided
practice by indicating that HIV prevention outreach should
focuson areaswhere individualsmeet partners (i.e., venues for
meeting anonymous partners) rather than in prisons or jails.
The HIV seropositivity rate at the STD clinic of 1.3%
overall and 4.1% among MSM is several magnitudes higher
than the general US population of 0.3%,1 but lower than
Table 3. (A) Latent Class Analysis Fit Indices
for 1–5 Class Model and (B) Average Class













1 Class -3405 (20) 6851 6869 0.000 NA
2 Classes -3178 (41) 6437 6475 0.000 0.81
3 Classes -3145 (62) 6415 6473 0.000 0.82
4 Classes -3080 (83) 6326 6404 0.000 0.81
5 Classes -3041 (104) 6290 6387 0.200 0.84
B.
Class 1 Class 2 Class 3 Class 4
Class 1 0.87 0.11 0.00 0.02
Class 2 0.04 0.89 0.00 0.07
Class 3 0.01 0.00 0.90 0.07
Class 4 0.02 0.05 0.03 0.92
Table 4. Latent Class Prevalence Rates for Classification Variables
Class 1
(N = 33; 7.3%)
Class 2
(N = 142, 31.6%)
Class 3
(N = 55; 12.2%)
Class 4
(N= 219; 48.8%)
Classification variable N (%) N (%) N (%) N (%)
Last HIV test
Never 9 (28.1) 70 (56.4) 34 (68.0) 55.0
Less than 1 year 13 (40.6) 16 (12.9) 0 (0.0) 10.6
1 year or more ago 10 (31.2) 38 (30.6) 16 (32.0) 34.3
# Oral sex partners last 12 months
0 partners 9 (27.3) 9 (6.4) 0 (0.0) 1 (0.5)
1 partner 18 (54.5) 55 (39.3) 0 (0.0) 0 (0.0)
2 partners 0 (0.0) 58 (41.4) 0 (0.0) 20 (9.3)
3–4 partners 0 (0.0) 18 (12.9) 8 (14.8) 62 (28.7)
5–10 partners 6 (18.2) 0 (0.0) 9 (16.7) 120 (55.6)
10+ partners 0 (0.0) 0 (0.0) 37 (68.5) 13 (6.0)
# Anal sex partners last 12 months
0 partners 10 (30.3) 12 (8.6) 0 (0.0) 15 (6.9)
1 partner 18 (54.5) 66 (47.1) 2 (3.8) 24 (11.1)
2 partners 1 (3.0) 49 (35.0) 0 (0.0) 24 (11.1)
3–4 partners 1 (3.0) 13 (9.3) 3 (5.7) 59 (27.2)
5–10 partners 3 (9.1) 0 (0.0) 16 (30.2) 92 (42.4)
10+ partners 0 (0.0) 0 (0.0) 32 (60.4) 3 (1.4)
Anonymous partner 12 (36.4) 16 (11.4) 55 (100) 161 (73.8)
Alcohol/drugs and sex 16 (48.5) 17 (12.1) 42 (76.4) 75 (34.4)
Sex with unknown HIV status 22 (66.7) 12 (8.6) 36 (65.4) 130 (59.6)
Prior STD last 12 months 1 (3.0) 16 (11.4) 22 (40.0) 41 (18.8)
Prior injection drug use 2 (6.1) 1 (0.7) 12 (22.2) 0 (0.0)
Ever exchanged sex 11 (33.3) 0 (0.0) 21 (38.2) 9 (4.1)
Forced sex 8 (24.2) 5 (3.6) 7 (12.7) 12 (5.5)
Ever incarcerated 11 (33.3) 0 (0.0) 8 (14.5) 0 (0.0)
STD, sexually transmitted disease.
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previous estimates of HIV prevalence amongMSM in the US
with higher prevalence among MSM of color and significant
geographic variation.37 These trends in HIV prevalence,
however, mask more complex latent classes, particularly
among MSM. Using latent class analysis, we were able to
identify a subgroup of MSM (Class 3) who may most benefit
from PrEP. Classes 2 and 4 reflected risk factors and HIV
prevalence that placed them in the second highest tier for HIV
infection risk. MSM from Class 1 had lower HIV prevalence
overall and may be less ideal candidates for PrEP.
Interestingly, incarceration and having been forced to have
sex were most common among Class 1, which had no HIV
infections in the group. The reasons behind a lack of asso-
ciation between incarceration and forced sex with HIV,
which are traditionally considered to be risk factors for
HIV,38–41 are likely reflective of the current HIV epidemic in
Rhode Island. Robust HIV screening and treatment programs
in the Rhode Island prison system and community-based
needle exchange programs have contributed to a decrease in
HIV transmission among incarcerated individuals and PWID
in Rhode Island;42,43 these programs may have had positive
spillover effects on patients in Class 1. Individuals in this
class reported fewer sexual partners, which may reflect an
overall lower HIV risk in this population. LCA identifies
clusters of characteristics that may identify individuals who
are at higher or lower risk of HIV; in this population, indi-
viduals with a history of incarceration and forced sex appear
to have lower risk for sexual acquisition of HIV, which may
explain this result.
The main characteristics among MSM in the highest risk
class included having more than 10 oral and anal sex partners
in the past year, history of prior STD(s), having anonymous
sex partners, and using drugs or alcohol use before or during
sex. These findings are consistent with prior studies focused
on individual risk behaviors impact on HIV infection14,44–46
and suggests that the combination of these risk factors cul-
minates in elevated HIV risk. Our results suggest that indi-
viduals in this latent class may benefit most from PrEP and
other HIV prevention interventions.
Previous reports among MSM suggest that prior STDs,
drug use, and having more than 10 sexual partners in the last
year are among the most robust predictors of HIV acquisi-
tion.17,46 More recent data suggest that social and sexual
network phenomena may also play an important role in ele-
vating HIV acquisition risks, particularly among MSM of
color.47,48 Although we did not have network-level data, the
LCA results suggest that individuals with similar demo-
graphic and behavioral patterns may, based on similar char-
acteristics, be in the same social or sexual networks that
facilitate HIV transmission.
Our findings suggest that focusing PrEP interventions on
MSM in the highest risk groups is important: MSM who
reported concurrent and anonymous partners and who re-
ported drug and alcohol use during sex had the highest
prevalence of HIV in our study. HIV-negative individuals in
those high-risk groups may benefit most from PrEP. Educa-
tional efforts targeting the highest risk networks may be
important for expanding PrEP uptake among those popula-
tions. Future work should also consider whether identifica-
tion of the highest risk group via a method such as LCA leads
to better uptake of PrEP and engagement in PrEP care
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traditional routes, and if this method may ultimately lead to a
reduced incidence of HIV.
Our study is subject to several limitations. Some behav-
ioral variables used in the LCA were not routinely collected
during the first year of the study but were added later.
Therefore, complete demographic and behavioral data were
available for most, but not all, patients who presented for
testing. There was also a relatively low number of newly
diagnosed HIV-positive individuals. This may have limited
the power of the study to identify significant risk factors for
infection. The results of this study arise from patients pre-
senting for care at a STD clinic, which may differs from
individuals receiving care at primary care or other clinics.
While the results of this study may not be generalizable to
other populations of MSM, the method for identification of
subpopulations that may benefit from PrEP could be repli-
cated in other populations. Nevertheless, our findings suggest
that LCA helped identify a group of MSM at highest risk for
acquiring HIV infection and most suitable for PrEP. Despite
its ability to discern interactions and patterns among multiple
HIV risk factors, LCA is largely a descriptive method. Future
replication of the analysis in larger, independent samples
would be useful to determine whether the same profiles
emerge reliably.
Furthermore, it may be important to conduct LCA using
additional risk factors, as more informative profiles with
greater predictive value may emerge. Future work should
also consider using LCA to evaluate incident HIV infection
in a prospective setting to determine risk factors in a more
rigorous manner.
Although CDC guidelines recommend that PrEP should be
considered for all MSM who have had any condomless anal
sex in the past 6 months or any STD diagnosed or reported in
the past 6 months,13 results from our analysis suggest that a
more nuanced public health approach may be useful for
identifying ideal candidates for PrEP. We found that com-
binations of behaviors in MSM, such as having anonymous
sexual partners, having more than 10 sexual partners, and
using drugs or alcohol during sex, are among the most useful
proxies for identifying those who are at highest risk for
contracting HIV. These patients may be the most ideal can-
didates for PrEP.
The findings from this analysis have informed clinical
practice in our own PrEP implementation program; this
method and our related findings have important implications
for clinical practice and for scaling up PrEP interventions
around the country.
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